FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2776954349> ?p ?o ?g. }

• W2776954349 endingPage "e586" @default.
• W2776954349 startingPage "e577" @default.
• W2776954349 abstract "Introduction Metastatic renal cell carcinoma (RCC) with a sarcomatoid component is a rare disease associated with a poor prognosis. We report the outcomes of 47 patients with metastatic sarcomatoid RCC (SRCC) treated with different modalities including chemotherapy, tyrosine kinase inhibitors, or immunotherapy over 2 decades in a French cancer center. Furthermore, we assessed the validity of prognostic scores in this subset of RCC. Patients and Methods Patients were retrospectively identified from the database of the pathology department of the University Hospital of Strasbourg. We enrolled all patients with RCC with a sarcomatoid component diagnosed between 1995 and 2016. Patients with nonmetastatic RCC were excluded. Recorded variables included: clinical stage, metastatic sites, pathologic stage, type of treatments, prognostic group, and survival data. The primary end point was overall survival. The institutional ethical committee approved the study protocol. Results Of 104 patients with SRCC, 47 patients with metastatic SRCC were included. The median age was 60 years (range, 41-77 years). Median length of follow-up was 34 months (range, 1-180 months). Fifty-five percent of patients had known metastases at diagnosis. Lung represented the first metastatic site (70%) followed by glandular (28%), bone (23%), liver (21%), and brain (6%). Fifteen percent of patients received immunotherapy including cytokine-based therapy (n = 7), or checkpoint inhibitors (n = 2). Moreover, 7 patients received chemotherapy. Five patients received no systemic treatment because of their poor performance status. Of 42 treated patients, 2 patients achieved complete response and 9 partial response (24%). Median overall survival was 13.3 months. International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic groups were valid in this subset of SRCC patients. A sarcomatoid percentage cutoff of 30% had the strongest influence on overall survival. Conclusion Despite the arrival of tyrosine kinase inhibitors 10 years ago, metastatic SRCC remains a disease of poor prognosis and difficult to treat. Chemotherapy regimen and targeted therapies showed little activity in SRCC. IMDC score is a relevant prognostic factor in SRCC patients. Additionally, the MSKCC score, the sarcomatoid percentage, the necrotic fraction, and the vascular invasion could prove useful in identifying patients with a more favorable prognosis. These findings could help toward better patient stratification in clinical trials. Prospective trials assessing new drugs including immune checkpoint inhibitors are currently ongoing to improve SRCC survival." @default.
• W2776954349 created "2018-01-05" @default.
• W2776954349 creator A5009618605 @default.
• W2776954349 creator A5023332819 @default.
• W2776954349 creator A5030902321 @default.
• W2776954349 creator A5047167664 @default.
• W2776954349 creator A5068597606 @default.
• W2776954349 creator A5070717869 @default.
• W2776954349 creator A5084067613 @default.
• W2776954349 creator A5084177861 @default.
• W2776954349 date "2018-06-01" @default.
• W2776954349 modified "2023-10-18" @default.
• W2776954349 title "Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience" @default.
• W2776954349 cites W1497468875 @default.
• W2776954349 cites W1931162541 @default.
• W2776954349 cites W1967013153 @default.
• W2776954349 cites W1978963119 @default.
• W2776954349 cites W2016919517 @default.
• W2776954349 cites W2019607817 @default.
• W2776954349 cites W2022249378 @default.
• W2776954349 cites W2041902889 @default.
• W2776954349 cites W2054148312 @default.
• W2776954349 cites W2055723398 @default.
• W2776954349 cites W2060145801 @default.
• W2776954349 cites W2076553764 @default.
• W2776954349 cites W2086273452 @default.
• W2776954349 cites W2091889350 @default.
• W2776954349 cites W2093356247 @default.
• W2776954349 cites W2099752220 @default.
• W2776954349 cites W2113322173 @default.
• W2776954349 cites W2121553275 @default.
• W2776954349 cites W2131444088 @default.
• W2776954349 cites W2136490715 @default.
• W2776954349 cites W2143782771 @default.
• W2776954349 cites W2143813821 @default.
• W2776954349 cites W2147382551 @default.
• W2776954349 cites W2153867442 @default.
• W2776954349 cites W2164584861 @default.
• W2776954349 cites W2211641796 @default.
• W2776954349 cites W2222086386 @default.
• W2776954349 cites W2286190652 @default.
• W2776954349 cites W2031360275 @default.
• W2776954349 doi "https://doi.org/10.1016/j.clgc.2017.12.005" @default.
• W2776954349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29395949" @default.
• W2776954349 hasPublicationYear "2018" @default.
• W2776954349 type Work @default.
• W2776954349 sameAs 2776954349 @default.
• W2776954349 citedByCount "13" @default.
• W2776954349 countsByYear W27769543492018 @default.
• W2776954349 countsByYear W27769543492019 @default.
• W2776954349 countsByYear W27769543492020 @default.
• W2776954349 countsByYear W27769543492021 @default.
• W2776954349 countsByYear W27769543492022 @default.
• W2776954349 countsByYear W27769543492023 @default.
• W2776954349 crossrefType "journal-article" @default.
• W2776954349 hasAuthorship W2776954349A5009618605 @default.
• W2776954349 hasAuthorship W2776954349A5023332819 @default.
• W2776954349 hasAuthorship W2776954349A5030902321 @default.
• W2776954349 hasAuthorship W2776954349A5047167664 @default.
• W2776954349 hasAuthorship W2776954349A5068597606 @default.
• W2776954349 hasAuthorship W2776954349A5070717869 @default.
• W2776954349 hasAuthorship W2776954349A5084067613 @default.
• W2776954349 hasAuthorship W2776954349A5084177861 @default.
• W2776954349 hasConcept C121608353 @default.
• W2776954349 hasConcept C126322002 @default.
• W2776954349 hasConcept C143998085 @default.
• W2776954349 hasConcept C2776694085 @default.
• W2776954349 hasConcept C2776907518 @default.
• W2776954349 hasConcept C2777472916 @default.
• W2776954349 hasConcept C2778822529 @default.
• W2776954349 hasConcept C2779984678 @default.
• W2776954349 hasConcept C71924100 @default.
• W2776954349 hasConceptScore W2776954349C121608353 @default.
• W2776954349 hasConceptScore W2776954349C126322002 @default.
• W2776954349 hasConceptScore W2776954349C143998085 @default.
• W2776954349 hasConceptScore W2776954349C2776694085 @default.
• W2776954349 hasConceptScore W2776954349C2776907518 @default.
• W2776954349 hasConceptScore W2776954349C2777472916 @default.
• W2776954349 hasConceptScore W2776954349C2778822529 @default.
• W2776954349 hasConceptScore W2776954349C2779984678 @default.
• W2776954349 hasConceptScore W2776954349C71924100 @default.
• W2776954349 hasIssue "3" @default.
• W2776954349 hasLocation W27769543491 @default.
• W2776954349 hasLocation W27769543492 @default.
• W2776954349 hasOpenAccess W2776954349 @default.
• W2776954349 hasPrimaryLocation W27769543491 @default.
• W2776954349 hasRelatedWork W1584669207 @default.
• W2776954349 hasRelatedWork W2008453265 @default.
• W2776954349 hasRelatedWork W2024340610 @default.
• W2776954349 hasRelatedWork W2024938637 @default.
• W2776954349 hasRelatedWork W2899528185 @default.
• W2776954349 hasRelatedWork W2899585536 @default.
• W2776954349 hasRelatedWork W3030034569 @default.
• W2776954349 hasRelatedWork W3031735911 @default.
• W2776954349 hasRelatedWork W3172671185 @default.
• W2776954349 hasRelatedWork W4210287142 @default.
• W2776954349 hasVolume "16" @default.
• W2776954349 isParatext "false" @default.

• next